Noble Financial Upgrades NanoViricides (NYSE:NNVC) to “Strong-Buy”

NanoViricides (NYSE:NNVC) was upgraded by analysts at Noble Financial to a “strong-buy” rating in a research report issued on Monday,Zacks.com reports.

NanoViricides Stock Performance

Shares of NYSE:NNVC remained flat at $1.50 during trading on Monday. The stock had a trading volume of 196,827 shares, compared to its average volume of 579,847. The stock has a fifty day moving average of $1.45 and a two-hundred day moving average of $1.21. The company has a market cap of $34.47 million, a PE ratio of -2.08 and a beta of 1.67. NanoViricides has a 12-month low of $0.85 and a 12-month high of $2.23.

Institutional Investors Weigh In On NanoViricides

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. State Street Corp raised its position in shares of NanoViricides by 29.4% in the fourth quarter. State Street Corp now owns 54,206 shares of the company’s stock valued at $61,000 after buying an additional 12,300 shares during the last quarter. Susquehanna International Group LLP boosted its position in NanoViricides by 37.4% during the third quarter. Susquehanna International Group LLP now owns 52,217 shares of the company’s stock worth $75,000 after acquiring an additional 14,217 shares during the last quarter. Geode Capital Management LLC boosted its position in NanoViricides by 9.4% during the fourth quarter. Geode Capital Management LLC now owns 174,371 shares of the company’s stock worth $197,000 after acquiring an additional 14,944 shares during the last quarter. Miller Financial Services LLC purchased a new stake in NanoViricides during the 4th quarter valued at about $81,000. Finally, Jane Street Group LLC purchased a new stake in NanoViricides during the 4th quarter valued at about $140,000. Institutional investors and hedge funds own 10.30% of the company’s stock.

About NanoViricides

NanoViricides, Inc is a clinical-stage biotechnology company focused on the development of novel antiviral therapies using its proprietary nanomicelle technology. The company designs polymeric, virus-targeted nanoviricides that seek to neutralize viral pathogens by binding to specific viral surface proteins and destroying their structural integrity. NanoViricides’ platform is intended to offer broad-spectrum activity against a range of enveloped viruses, positioning it as a potential solution for both existing and emerging viral threats.

The company’s pipeline includes preclinical and early clinical candidates targeting seasonal and pandemic influenza strains, as well as investigational programs for coronaviruses, hepatitis, dengue, HIV and other viruses.